Seizures Market Report 2026

Seizures Market Report 2026
Global Outlook – By Drug Type (First Generation Anti-Epileptics, Second Generation Anti-Epileptics, Third Generation Anti-Epileptics), By Route Of Administration (Oral, Parenteral, Rectal Administration), By Distribution Channel (Hospitals Pharmacies, Independent Pharmacies, Online Pharmacies), By End-User (Hospitals And Clinics, Ambulatory Surgical Centers, Homecare Settings, Other End-Users) - Market Size, Trends, And Global Forecast 2026-2035
Seizures Market Overview
• Seizures market size has reached to $4.34 billion in 2025 • Expected to grow to $5.75 billion in 2030 at a compound annual growth rate (CAGR) of 5.7% • Growth Driver: Rising Traumatic Brain Injuries Fueling The Growth Of The Market Due To Increasing Road Accidents • Market Trend: Innovative Buccal Film Technology Advancing Seizure Treatment Accessibility • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.What Is Covered Under Seizures Market?
Seizures refer to sudden, uncontrolled electrical activity in the brain that can lead to changes in movement, behavior, sensation, or awareness. They occur due to abnormal neuronal activity and can be triggered by epilepsy, head injuries, infections, or other medical conditions. The main drug types of seizures are first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. First-generation anti-epileptic drugs (AEDs) refer to the earliest class of medications developed for the treatment of epilepsy. The multiple routes of administration are oral, parenteral, and topical. They are distributed through various channels including hospital pharmacies, independent pharmacies, and online pharmacies, and are used by several end-users such as hospitals and clinics, ambulatory surgical centers, homecare settings, and others.
What Is The Seizures Market Size and Share 2026?
The seizures market size has grown strongly in recent years. It will grow from $4.34 billion in 2025 to $4.6 billion in 2026 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to growing prevalence of epilepsy, improved diagnostic awareness, availability of anti-epileptic drugs, rise in healthcare spending, technological advances in EEG devices.What Is The Seizures Market Growth Forecast?
The seizures market size is expected to see strong growth in the next few years. It will grow to $5.75 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to AI-enabled seizure prediction tools, remote patient monitoring adoption, personalized therapy solutions, expansion of neurology-focused telehealth, novel neurostimulation devices. Major trends in the forecast period include wearable seizure monitoring devices, home-based EEG solutions, AI-driven seizure prediction, tele-neurology consultations, integration with health apps.Global Seizures Market Segmentation
1) By Drug Type: First Generation Anti-Epileptics, Second Generation Anti-Epileptics, Third Generation Anti-Epileptics 2) By Route Of Administration: Oral, Parenteral, Rectal Administration 3) By Distribution Channel: Hospitals Pharmacies, Independent Pharmacies, Online Pharmacies 4) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Homecare Settings, Other End-Users Subsegments: 1) By First Generation Anti-Epileptics: Phenytoin, Carbamazepine, Valproate, Phenobarbital, Primidone, Ethosuximide 2) By Second Generation Anti-Epileptics: Lamotrigine, Levetiracetam, Topiramate, Oxcarbazepine, Zonisamide, Gabapentin, Pregabalin 3) By Third Generation Anti-Epileptics: Lacosamide, Perampanel, Brivaracetam, Eslicarbazepine, CenobamateWhat Is The Driver Of The Seizures Market?
The increasing prevalence of traumatic brain injuries is expected to propel the growth of the seizures market going forward. Traumatic brain injuries (TBI) refer to damage to the brain caused by a sudden external force, such as a blow, jolt, or penetrating injury to the head. Traumatic brain injuries are increasing due to the rising number of road accidents, as high-speed collisions and distracted driving lead to more severe head injuries. Seizures can serve as an early indicator of traumatic brain injuries, helping doctors diagnose and manage underlying brain damage more effectively. For instance, in October 2023, according to the World Federation of Neurology, a UK-based organization committed to advancing neurological practice and research worldwide, more than 40% of the global population is affected by a neurological condition, a figure anticipated to nearly double by 2050. Therefore, the increasing prevalence of traumatic brain injuries is driving the growth of the seizures industry.Key Players In The Global Seizures Market
Major companies operating in the seizures market are Johnson & Johnson Service Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., UCB S.A., Eisai Co. Ltd., H. Lundbeck A S, Zydus Lifesciences Limited, SK Biopharmaceuticals Co. Ltd., Supernus Pharmaceuticals Inc., Taro Pharmaceutical Industries Ltd., Marinus Pharmaceuticals Inc., Eton Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc., Pfizer Inc., Abbott Laboratories, Cipla Limited, Dr Reddy’s Laboratories Ltd., Aurobindo Pharma LimitedGlobal Seizures Market Trends and Insights
Major companies operating in the seizures market are developing innovative products, such as buccal film, to enhance treatment accessibility and patient compliance. The buccal film refers to a thin, dissolvable strip that is administered by placing it against the inner lining of the cheek (buccal mucosa), where the drug is absorbed directly into the bloodstream. For instance, in December 2024, Aquestive Therapeutics Inc., a US-based pharmaceutical company, received U.S. FDA approval for orphan drug exclusivity for Libervant (diazepam) buccal film, intended for pediatric patients aged two to five with seizure clusters. This innovative formulation offers a non-invasive, easy-to-administer alternative to traditional diazepam delivery methods, ensuring rapid absorption through the buccal mucosa for faster onset of action. As the first and only orally administered diazepam film approved for this age group, Libervant aims to improve caregiver convenience and enhance patient compliance. This exclusivity further strengthens Aquestive's position in advancing oral film-based epilepsy therapies.What Are Latest Mergers And Acquisitions In The Seizures Market?
In April 2024, Harmony Biosciences, a US-based biopharmaceutical company, acquired Epygenix Therapeutics for an undisclosed amount With this acquisition, Harmony Biosciences aims to bolster its epilepsy pipeline by gaining EPX‑100, a lead candidate for Dravet syndrome and Lennox‑Gastaut syndrome, thereby deepening its focus in the seizure treatment market. Epygenix Therapeutics is a US-based precision-medicine biopharma company developing therapies for rare genetic epilepsies.Regional Outlook
North America was the largest region in the seizures market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.What Defines the Seizures Market?
The seizures market consists of sales of neurostimulation devices, wearable seizure detection devices, and medical cannabis products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.What Key Data and Analysis Are Included in the Seizures Market Report 2026?
The seizures market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the seizures industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Seizures Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $4.6 billion |
| Revenue Forecast In 2035 | $5.75 billion |
| Growth Rate | CAGR of 6.0% from 2026 to 2035 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 - 2035 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2035 |
| Segments Covered | Drug Type, Route Of Administration, Distribution Channel, End-User |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, ... |
| Key Companies Profiled | Johnson & Johnson Service Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., UCB S.A., Eisai Co. Ltd., H. Lundbeck A S, Zydus Lifesciences Limited, SK Biopharmaceuticals Co. Ltd., Supernus Pharmaceuticals Inc., Taro Pharmaceutical Industries Ltd., Marinus Pharmaceuticals Inc., Eton Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc., Pfizer Inc., Abbott Laboratories, Cipla Limited, Dr Reddy’s Laboratories Ltd., Aurobindo Pharma Limited |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |
Frequently Asked Questions
The Seizures market was valued at $4.34 billion in 2025, increased to $4.6 billion in 2026, and is projected to reach $5.75 billion by 2030.
request a sample hereThe global Seizures market is expected to grow at a CAGR of 5.7% from 2026 to 2035 to reach $5.75 billion by 2035.
request a sample hereSome Key Players in the Seizures market Include, Johnson & Johnson Service Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., UCB S.A., Eisai Co. Ltd., H. Lundbeck A S, Zydus Lifesciences Limited, SK Biopharmaceuticals Co. Ltd., Supernus Pharmaceuticals Inc., Taro Pharmaceutical Industries Ltd., Marinus Pharmaceuticals Inc., Eton Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc., Pfizer Inc., Abbott Laboratories, Cipla Limited, Dr Reddy’s Laboratories Ltd., Aurobindo Pharma Limited .
request a sample hereMajor trend in this market includes: Innovative Buccal Film Technology Advancing Seizure Treatment Accessibility. For further insights on this market.
request a sample hereNorth America was the largest region in the seizures market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the seizures market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
request a sample here